Proto-Script Pharmaceuticals, Corp. entered into a share exchange agreement to acquire Yanex Group, Inc. (OTCPK:YNXG) in a reverse merger transaction on June 29, 2016. Under the terms, Yanex Group will acquire 100% of the issued and outstanding common stock of Proto-Script Pharmaceuticals, in exchange for 30 million restricted shares of Yanex Group’s common stock. Accordingly, Yanex Group will become a wholly-owned subsidiary of the Yanex Group and the business direction of Yanex Group will shift to the business of Proto-Script Pharmaceuticals. On June 29, 2016, Leonardo Correa Rodriguez resigned from all positions with Yanex Group, including Director, President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer, and as of June 29, 2016, Michelle Rico was appointed as the sole member of Yanex Group’s Board of Directors and as the Yanex Group’s President, Chief Executive Officer, Chief Financial Officer, Treasurer, and Secretary. The transaction is subject to conditions including approvals of any governmental or regulatory authority among others. Proto-Script Pharmaceuticals, Corp. completed the acquisition of Yanex Group, Inc. (OTCPK:YNXG) in a reverse merger transaction on June 29, 2016.